Screener
Rapport Therapeutics, Inc. RAPP Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $63,612 | $52,645 |
| Accounts receivable | 293 | — |
| Short-term investments | 372,465 | 437,894 |
| Restricted cash | 105 | 105 |
| Prepaid expenses and other current assets | 10,381 | 7,917 |
| Total current assets | 446,856 | 498,561 |
| Property and equipment, net | 2,337 | 2,976 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s short-term investments?
- Rapport Therapeutics, Inc. (RAPP) reported short-term investments of $372.47M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s short-term investments changed year-over-year?
- Rapport Therapeutics, Inc.'s short-term investments increased by 81.4% year-over-year, from $205.38M to $372.47M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s short-term investments?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s short-term investments has grown at a 138.0% compound annual growth rate (CAGR), from $77.31M to $437.89M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Rapport Therapeutics, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude